Copenhagen University Hospital, Rigshospitalet
Copenhagen, 2100, Denmark
Location status: Recruiting
NCT Number: NCT06294990
The goal of this randomized clinical trial is to study the effect of testosterone replacement therapy during puberty in boys with Klinefelter syndrome (KS, 47,XXY).
The main questions to answer are how treatment with testosterone will affect body fat mass, lipid and glucose metabolism, growth and body proportions, bone mineralization as well as effects on neurocognitive development and emotional and social difficulties.
Participants will be randomized to two years treatment with testosterone or placebo.
Interested in participating?
Request Info10 year–14 year
Male
Interventional
Phase 4
Copenhagen, 2100, Denmark
Location status: Recruiting
Klinefelter syndrome (KS, 47,XXY) is the most frequent sex chromosome disorder with a prevalence of 1:660 boys. Patients with KS are hypogonadal due to a progressive testicular destruction starting already in childhood. Consequently, the adult male with KS is characterized by small testes, signs of incomplete virilization (e.g. lack of voice deepening, sparse face and body hair, gynecomastia, low muscle mass, reduced penile length), hypergonadotropic hypogonadism, infertility and increased risk of metabolic syndrome, diabetes, cardiovascular disease, osteoporosis and psychosocial and neurodevelopmental challenges. Adults with KS have a poor health and a prevention of the major co-morbidities associated with KS and thereby an improvement in the general health would have an enormous impact on the life of a large cohort of males worldwide.
Sufficient testosterone is not only important in the adult but also during puberty and adolescence for a normal virilization and to improve body composition and body proportions, as well as to maximize peak bone mass acquisition. It has therefore been internationally accepted and makes biological sense to consider testosterone replacement therapy (TRT) during puberty in KS. However, there are no evidence based recommendations, and during recent years TRT in puberty has been questioned and is no longer recommended in some countries. There is a need on an international level for evaluating the effect of this treatment. We therefore aim at evaluating the effect of 2 years TRT during early puberty in boys with KS aged 10 to 14 years in this national, multi-center, randomized, double-blind, placebo-controlled intervention study. The primary endpoint is to evaluate the effect on body fat mass. The secondary endpoints are to evaluate effects on lipid and glucose metabolism, growth and body proportions, bone mineralization as well as effects on neurocognitive development and emotional and social difficulties.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two years treatment with testosterone
Other names: Testosterone
Two years treatment with placebo
Other names: Testosterone
Time frame: Baseline and 1 and two years
Evaluation of body fat percentage by whole body dual energy x-ray absorptiometry (DEXA) scan
Time frame: Every three months for two years
Tanner genital (G) staging from G1 to G5. G1 is the prepubertal stage and G5 is the fully develloped stage.
Time frame: Every three months for two years
Tanner pubic hair (PH) staging from PH1 to PH6. PH1 is the prepubertal stage and PH6 is the fully develloped stage.
Time frame: Every three months for two years
Measurement of voice frequency using the app "Voice Analyst" (Speechtools Ltd.).
Time frame: Every three months for two years
Evaluation of testicular volume by palpation with orchidometer
Time frame: Every three months for two years
Presence of gynecomastia (yes/no)
Time frame: Every three months for two years
Measurement of luteinizing hormone (LH) (IU/L) in serum
Time frame: Every three months for two years
Measurement of serum concentration of testosterone (nmol/L)
Time frame: Every three months for two years
Measurement of folliclestimulating hormone (FSH) (IU/L) in serum
Time frame: Every three months for two years
Measurement of serum concentration of estradiol (pmol/L)
Time frame: Every three months for two years
Measurement of serum concentration of inhibin B (ng/L)
Time frame: Every three months for two years
Measurement of serum concentration of anti mullerian hormone (AMH) (pmol/L)
Time frame: At base line, and at 1 and 2 years
Measurement of the concentration of luteinizing hormone (LH) and follicle stimulating hormone (FSH) in the first, fasting, morning voiding. Measured in IU/L.
Time frame: Every three months for two years
Measurement of height (cm)
Time frame: Every three months for two years
Measurement of weight (kg)
Time frame: Every three months for two years
Measurement of sitting height (cm)
Time frame: At base line, and at 1 and 2 years
Measurement of head circumference (cm)
Time frame: At base line, and at 1 and 2 years
Measurement of arm span (cm)
Time frame: At baseline and at 1 and two years
Measurement of whole body bone mineral content (BMC) evaluated by whole body DXA scan
Time frame: At base line, and at 1 and 2 years
Evaluation of bone health index (BHI) from X-ray of left hand and evaluated using the software BoneXpert version 3 (Hørsholm, Denmark)
Time frame: At base line, and at 1 and 2 years
Measurement of 25-OH-vitamin D in blood sample
Time frame: At base line, and at 1 and 2 years
Measurement of calcium in blood sample
Time frame: At base line, and at 1 and 2 years
Measurement of phosphate in blood sample
Time frame: At base line, and at 1 and 2 years
Measurement of parathyroid hormone (PTH) in blood sample
Time frame: At base line, and at 1 and 2 years
Measurement of carboxy terminal telopeptide of collagen type I (CTX) in blood sample
Time frame: At base line, and at 1 and 2 years
Measurement of alkaline phosphatase in blood sample
Time frame: At base line, and at 1 and 2 years
Measurement of osteocalcin in blood sample
Time frame: At base line, and at 1 and 2 years
Measurement of procollagen type I N-terminal peptide (PINP) in blood sample
Time frame: Base line and at 1 and 2 years
Evaluation of bone age by X-ray of left hand and evaluated using the software BoneXpert version 3 (Hørsholm, Denmark)
Time frame: At base line, and at 1 and 2 years
Measurement of IGF1, IGF2, IGF1BP-1-6 and acid-labile subunit (ALS)) (microg/L)
Time frame: Every three months for two years
Measurement of standing jump length (cm)
Time frame: Every three months for two years
Measurement of hand grip strength using a digital hand dynamometer (Baseline BIMS, digital hand dynamometer, functional model)
Time frame: Base line and at 1 and 2 years
Evaluation of QT Interval with electrocardiogram (ECG)
Time frame: Base line and at 1 and 2 years
Measurement of cholesterol in blood sample
Time frame: Base line and at 1 and 2 years
Measurement of adiponectin in blood sample
Time frame: Base line and at 1 and 2 years
Measurement of leptin in blood sample
Time frame: Base line and at 1 and 2 years
Measurement of glucose in blood sample
Time frame: Base line and at 1 and 2 years
Measurement of insulin in blood sample
Time frame: Base line and at 1 and 2 years
Measurement of HbA1C in blood sample
Time frame: Base line and at 1 and 2 years
Measurement of CRP in blood sample
Time frame: Baseline and after two years
The Weschler Intelligence Scale for Children - Fifth Edition (WISC-V). The result is based on a combination of seperate index scores. A higher score generally indicates stronger cognitive abilities.
Time frame: Baseline and after two years
The Test of Variables of Attention, version 9 (T.O.V.A) is a computerized, performance-based assessment tool used to measure attention and impulsivity. The result is based on a combination of scores.
Time frame: Baseline and after two years
The Test of Memory and Learning, Second Edition (Tomal-2). The results are presented as standard scores, scaled scores, percentile ranks, and index scores. A higher score is a better outcome.
Time frame: Baseline and after two years
The Judgement of Line Orientation Test. The result is based on a combination of scores. Higher scores indicate better visual-spatial judgment.
Time frame: Baseline and after two years
The Mental Rotation Test
Time frame: Baseline and after two years
The Beery-Buktenica Developmental Test of Visual-Motor Integration
Time frame: Baseline and after two years
The Baseline Speed subtask of the Amsterdam Neuropsychological Tasks program (ANT)
Time frame: Baseline and after two years
The Children's Communication Checklist (CCC-2). The result is evaluated based on 10 subscores. Higher scores indicate stronger communication skills.
Time frame: Baseline and after two years
The Social Responsiveness Scale-2 (SRS-2) is a standardized questionnaire used to assess social behavior and autism-related traits. Higher scores indicate greater social difficulties, while lower scores suggest stronger social skills.
Time frame: Baseline and after two years
The Delis-Kaplan Executive Function System (D-KEFS). Higher scores indicate better executive functioning, while lower scores may suggest difficulties with problem-solving, impulse control, or flexibility.
Time frame: Baseline and after two years
The Behavior Rating Inventory of Executive Function, Second Edition rating scale , parent version (BRIEF-2) assesses executive functioning. The result is based on a combination of scores. Higher scores indicate greater executive function difficulties.
Time frame: Baseline and after two years
Behavior Assessment System for Children, Third Edition (BASC-3), parent and self-report version. The result is based on a combination of scores. A higher score indicates more difficulties.
Time frame: Baseline and after two years
Self-report version of The Multidimensional Anxiety Scale for Children - 2nd edition (MASC-2). The result is based on a combination of scores. Higher scores suggest greater levels of anxiety and more severe symptoms.
Time frame: Baseline and after two years
The parent version of the ADHD-rating scale. The result is based on a combination of scores. Higher scores on the inattention and hyperactivity/impulsivity subscales suggest more significant ADHD symptoms.
Time frame: Baseline and after two years
The Adaptive Behavior Assessment System, Third Edition (ABAS-III) is a comprehensive tool used to assess adaptive functioning. The result is based on a combination of scores. A higher score indicates better adaptive functioning.
Time frame: Baseline and after two years
The Beck Youth Self-Concept Inventory is a tool designed to assess self-concept and self-esteem in children and adolescents. A high percentile rank (above 70) indicates a strong self-concept, while a low percentile rank (below 30) suggests low self-esteem or dissatisfaction.
Time frame: Baseline and after two years
PedsQL Multidimentional Fatigue Scale, parent, and self-report versions is a tool designed to assess fatigue levels in children and adolescents. The result is based on a combination of scores. A higher score indicates less fatigue (better energy levels and functioning). A lower score indicates more fatigue, suggesting that fatigue is significantly affecting the child's daily activities.
Time frame: After 2 years
If the patient is able and willing he will have the possibility to deliver a semen sample for cryopreservation of potential spermatozoa
Time frame: At base line, and at 1 and 2 years
The effects on epigenetics will be evaluation by evaluating changes in DNA methylation patterns. This will be analyzed on DNA from white blood cells by applying Illumina methylation arrays.
Time frame: At base line, and at 1 and 2 years
DNA will be analyzed using a selected set of genetic polymorphisms in target genes with established or theoretic effects on hormone production and hormone receptor sensitivity. They will be analysed either by PCR genotyping or targeted sequencing (max. 200 selected genes). SNP arrays that exclusively target common variants, and not any rare variants, will be used to determine the influence of common genetic variation on the observed associations.
Time frame: At base line, and at 1 and 2 years
RNA analysis of circulating, small, non-coding RNA will be performed as a biomarker for the circulating concentrations of reproductive hormones and for overweight.
Contact information is provided by the study sponsor or research team.
Lise Aksglæde
Other
Klinefelter Syndrome - the Effect of Testosterone Treatment in Puberty. a Randomized, Double-blind Placebo-controlled Intervention Study: 'The TiPY Study'
Acronym: TiPY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05586802
Chromosome Disorders, Congenital Abnormalities
Lausanne, Switzerland
View Trial DetailsNCT05581147
Autoimmune Diseases, Chromosome Disorders
Roma, Italy
View Trial DetailsNCT03396562
47, XYY syndrome, 49,XXXXX syndrome
Aurora, Colorado, United States
View Trial DetailsNCT03836300
22q11 Deletion Syndrome, Abnormalities, Multiple
Research Triangle Park, North Carolina, United States
View Trial Details